Cephalalgia : an international journal of headache
-
Randomized Controlled Trial Multicenter Study
Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Sustained pain freedom is an important attribute of acute migraine therapies for patients and physicians. Here we report efficacy of the centrally penetrant, highly selective, 5-HT1F agonist lasmiditan on sustained pain freedom and other outcomes at 24 and 48 hours post-dose. ⋯ SAMURAI: NCT02439320; SPARTAN: NCT02605174.
-
Randomized Controlled Trial
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
Previously published three-month placebo-controlled and one-year open-label clinical trial data have provided information on the efficacy and safety of erenumab. ⋯ In this long-term study of a CGRP-receptor antibody, erenumab was found to be safe and well-tolerated with a spectrum and rate of adverse events consistent with shorter-term placebo-controlled studies.